Mireia Melé

890 total citations
21 papers, 138 citations indexed

About

Mireia Melé is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Mireia Melé has authored 21 papers receiving a total of 138 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Mireia Melé's work include Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (7 papers) and BRCA gene mutations in cancer (6 papers). Mireia Melé is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (7 papers) and BRCA gene mutations in cancer (6 papers). Mireia Melé collaborates with scholars based in Spain, United Kingdom and Germany. Mireia Melé's co-authors include Serafín Morales, Noelia Martínez-Jáñez, Josep Gumà, Patricia Villagrasa, Sònia Pernas, Lourdes Martorell, Luís Manso, Meritxell Bellet, Bárbara Roig and B. Ojeda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Mireia Melé

19 papers receiving 135 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mireia Melé Spain	7	81	39	37	29	25	21	138
Kathleen Harnden United States	7	74 0.9×	37 0.9×	62 1.7×	25 0.9×	33 1.3×	15	144
Victoria Damerell South Africa	7	52 0.6×	30 0.8×	45 1.2×	87 3.0×	18 0.7×	8	161
Shan Muhammad China	8	93 1.1×	61 1.6×	32 0.9×	89 3.1×	13 0.5×	15	223
Alexandra M. Moore United States	7	99 1.2×	54 1.4×	40 1.1×	81 2.8×	9 0.4×	19	240
Ekaterini Christina Tampaki Switzerland	8	61 0.8×	32 0.8×	12 0.3×	56 1.9×	4 0.2×	15	147
Nathalie Cornez Belgium	6	92 1.1×	32 0.8×	18 0.5×	28 1.0×	6 0.2×	12	130
Beryl Leirvaag Norway	7	63 0.8×	46 1.2×	22 0.6×	82 2.8×	32 1.3×	7	151
Nicholas A. Ullman United States	5	135 1.7×	33 0.8×	23 0.6×	35 1.2×	7 0.3×	10	196
Rebeca Alba Rubío Germany	6	67 0.8×	20 0.5×	49 1.3×	70 2.4×	17 0.7×	10	160

Countries citing papers authored by Mireia Melé

Since Specialization

Citations

This map shows the geographic impact of Mireia Melé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mireia Melé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mireia Melé more than expected).

Fields of papers citing papers by Mireia Melé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mireia Melé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mireia Melé. The network helps show where Mireia Melé may publish in the future.

Co-authorship network of co-authors of Mireia Melé

This figure shows the co-authorship network connecting the top 25 collaborators of Mireia Melé. A scholar is included among the top collaborators of Mireia Melé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mireia Melé. Mireia Melé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ciruelos, Eva, Tomás Pascual, Isabel Blancas, et al.. (2025). SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.. Journal of Clinical Oncology. 43(16_suppl).

Rodríguez, A., Ariadna Roqué, A. Fernandez Ortega, et al.. (2025). 270P First-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with a homologous recombination repair (HRR) germline pathogenic variant (PV) and breast cancer (BC): Clinical outcomes and mechanisms of resistance. ESMO Open. 10. 104825–104825. 1 indexed citations

Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008. 4 indexed citations

Fernández‐Castillejo, Sara, Bárbara Roig, Mireia Melé, et al.. (2023). Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer. Journal of Medical Genetics. 61(1). 69–77.

Turner, Nicholas C., Frederik Marmé, Sung‐Bae Kim, et al.. (2023). Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.. Journal of Clinical Oncology. 41(16_suppl). 502–502. 3 indexed citations

Haba-Rodríguez, Juan de la, Antonio Antón, Vanesa Quiroga, et al.. (2023). Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).. Journal of Clinical Oncology. 41(16_suppl). 1093–1093. 1 indexed citations

Torres, Alexandra, et al.. (2022). Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 41(5). 284–291. 2 indexed citations

Ciruelos, Eva, Sònia Pernas, Javier Cortés, et al.. (2022). 208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial. Annals of Oncology. 33. S222–S223. 2 indexed citations

Ciruelos, Eva, Javier Cortés, Sònia Pernas, et al.. (2021). 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype. Annals of Oncology. 32. S77–S77. 2 indexed citations

10.

Gil‐Gil, Miguel, Meritxell Bellet, Serafín Morales, et al.. (2021). Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 11. 645026–645026. 8 indexed citations

11.

Schmid, Peter, Begoña Bermejo, Melissa Phillips, et al.. (2021). 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer. Annals of Oncology. 32. S411–S412. 6 indexed citations

12.

Arenas, Meritxell, Salvador Fernández‐Arroyo, Elisabet Rodríguez‐Tomàs, et al.. (2019). Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy. Clinical & Translational Oncology. 22(7). 1078–1085. 8 indexed citations

13.

Roig, Bárbara, et al.. (2019). Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Clinical Biochemistry. 76. 17–23. 10 indexed citations

14.

Roig, Bárbara, et al.. (2018). Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients. Clinical & Translational Oncology. 20(9). 1226–1231. 7 indexed citations

15.

Haba-Rodríguez, Juan de la, Ángel Guerrero‐Zotano, José Alejandro Pérez Fidalgo, et al.. (2018). A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. Journal of Clinical Oncology. 36(15_suppl). TPS1114–TPS1114. 4 indexed citations

16.

Prat, Aleix, Mafalda Oliveira, Lorena de la Peña, et al.. (2017). SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer. Annals of Oncology. 28. v106–v107. 4 indexed citations

17.

Roig, Bárbara, Lourdes Martorell, Mireia Melé, et al.. (2016). In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample. Cancer Genetics. 209(11). 487–492. 8 indexed citations

18.

Gil‐Gil, Miguel, Meritxell Bellet, Serafín Morales, et al.. (2015). Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Research and Treatment. 151(3). 597–606. 39 indexed citations

19.

Sirgo, Agustina, et al.. (2009). Deterioro cognitivo inducido por los tratamientos oncológicos sistémicos en el cáncer de mama no metastático: revisión de estudios. SHILAP Revista de lepidopterología. 3 indexed citations

20.

Melé, Mireia, et al.. (2008). Fatal pneumonitis induced by oxaliplatin. Clinical & Translational Oncology. 10(11). 764–767. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact